MEDPMedpace Holdings, Inc.
Price
+23%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality strong, nothing alarming, price roughly fair, growing in the filings, the market undecided.
We are one of the world’s leading clinical contract research organizations, or CROs, by revenue, solely focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Our mission is to accelerate the global development of safe and effective medical therapeutics. We differentiate ourselves from our competitors by our disciplined operating model centered on providing full-service Phase I-IV clinical development services and our therapeutic expertise.
In the company’s own words · 10-K filed Feb 10, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Medpace Holdings, Inc. (MEDP) reported revenue of $707M in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with a gross margin of 29% and net income of $121M (17% of revenue). For the full year FY2025, revenue was $2.53B (+20% year on year) and net income $451M. Its largest product in Q2 2026 was Metabolic at $219M, 31% of the disclosed total, just ahead of Oncology at 30%. The next results filing is expected around Oct 21, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 22, 2026Medpace Holdings, Inc. Reports Second Quarter 2026 Results.Earnings release · press release
- Jun 4, 2026Effective June 1, 2026, Medpace Holdings, Inc. (the “Company”) appointed Brad W. Hansman, age 43, to the position of Executive Vice President, Operations.Director or officer change · Form 8-K
- May 19, 2026At the Medpace Holdings, Inc. (the “Company”) 2026 Annual Meeting of Stockholders held on May 15, 2026 (the “2026 Annual Meeting”), stockholders approved separate amendments (the “Amendments”) to the Restated Certificate of Incorporation of the Company, each as described in the Company’s proxy materials related to the …Charter/bylaw amendment or fiscal-year change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $707.3MThe company’s own SEC segment disclosure.
- Metabolic$219.1M31%
- Oncology$209.4M30%
- Other$98.3M14%
- Central Nervous System$82.9M12%
- Cardiology$60.0M8%
- Antiviral And Anti Infective$37.8M5%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Diagnostics & Research
Ranks #1 of 21 by RyuScore